Our Logo

1.0 LPBI Group’s Team created

Ten Intellectual Property Asset Classes

https://pharmaceuticalintelligence.com/2019-vista/

Contributors were:

UPDATED on 9/12/2020

SEE

2.0 LPBI Executive Summary – password Protected – request access by Contacting us

https://pharmaceuticalintelligence.com/leaders-in-pharmaceutical-business-intelligence/

UPDATED on 8/19/2020  

2020 VISTA 1.0 LPBI

https://pharmaceuticalintelligence.com/2019-vista/ 

2.0 LPBI Group’s Team

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

are executing Six New Strategies for 1.0 LPBI Group’s

Ten Intellectual Property Asset Classes

What are the Pipelines for 2021 – 2025?

2.0 LPBI – Executive Summary

A New Team was put in place for the development of the pipelines defining the future prospect of 1.0 LPBI Group’s portfolio of IP and the opportunities for  2.0 LPBI Group’s Team.

2.0 LPBI Group’s Team

• Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
• Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
• Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
• Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
• Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
• Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
• Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
• Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
• Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

2020-21 Visions include the Pipelines and the Plans for 2.0 LPBI: 2021 – 2025

https://pharmaceuticalintelligence.com/vision/

LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible. The challenge for the future is the development of several, i.e., the following six new strategies for creation of Value added Services and Products.

2.0 LPBI  – 2021 and Beyond

The New Strategies: TNS #1, #2, #3, #4, #5, #6

TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: a Partner has lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Biotech Accelerator for Drug Discovery: 

• We worked together in 2015-2016 for 2 years – Plan for 2020-2021: Galectins explored as drug-able by Scientists using Synthetic Biology to design new drug molecules
•  INTERNS are joining after Labor Day – they need to gain some LAB Flavor in return for working as Volunteers @LPBI projects: SEE
• 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
• 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP) 9/2020 – 9/2021

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

AVIVA’S VISION on 7/20/2020

Initiative #1:

Three new entries for WIKIPEDIA were created in July-August 2020

Wikipedia entry #1: Submitted for Review, 8/10/2020

1.0 LPBI

This entry was created by Zack and Aviva

• Uploaded by ZACH – Internal Review by Wikipedia, 8/10/2020
• Updates to include Using 12 Word Clouds for CHARTING the KNOWLEDGE MAPS in our 12 TOP VIEWED articles

Wikipedia entry #2: Submitted for Review, 8/10/2020

Wikipedia entry for The Founder of 1.0 LPBI and 2.0 LPBI – Aviva Lev-Ari, PhD, RN 

This entry was created by Zack fromlive URLs on the system with comments by MWF, GST, JTS

• Uploaded by ZACH – Internal Review by Wikipedia, 8/10/2020
• Updates to include her curations included in the 12 TOP VIEWED articles.

Wikipedia entry #3: 2.0 LPBI – Work-in-Progress

2.0 LPBI: 2021 and Beyond

This ENTRY will cover The New Strategies: TNS #1, #2, #3, #4, #5, #6

TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health

• Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed byLPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery 
• Inputs for Proof of Concept are the following three:

(1) Top 12 articles by views (all domains)

(2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1

(3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1

Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:

Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2

• Expand applications of Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
• Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
• Application on the ingress TEXT from:

Series C: e-Books on Cancer & Oncology

Volume 1:

Cancer Biology and Genomics for Disease Diagnosis

http://www.amazon.com/dp/B013RVYR2K 

Volume 2:

Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

http://www.amazon.com/dp/B071VQ6YYK 

and

Series B: Frontiers in Genomics Research

Volume 1: 

Genomics Orientations for Personalized Medicine

http://www.amazon.com/dp/B018DHBUO6

Volume 2:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

• The Wolfram Solution for Biological Sciences
• The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

LPBI Group’s FOUR Corpuses

(1) All 6,000 Journal Articles 

(2) 16 Books in Medicine 

(3) 60 e-Proceedings & 36 Tweet Collections of TOP Global Medical and Biotech Conferences, 2013 – 2020

(4) Content Segmentation by other criteria for Narrow casting the content of the journal ontology, Categories of Research (N = 715). About 70% are related to Drug Discovery

TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: a Partner had lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Biotech Accelerator for Drug Discovery: 

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Initiative #2:

Planning & Launch of a New Web Site for 2.0 LPBI – work-in-progress

Website Design for The New Strategies (TNS)

• Work to start by Gail, Aviva in October 2020

OUR HISTORY

• 1.0 LPBI is our Current Website http://pharmaceuticalintelligence.com 
• Calling 4/2012 to 12/2020 (1.0 LPBI) – OUR HISTORY
• It will become the BACKEND of the New Web Site, aka, 2.0 LPBI

OUR FUTURE

• 2.0 LPBI – will be our NEW WEB SITE about 2021 and BEYOND
• Work on the New WEBSITE to start in September 2020 by Gail, Aviva 

Initiative #3:

New Industry Partnerships

2.0 LPBI: 2021 and Beyond

In Details – The New Strategies: TNS #1, #2, #3, #4, #5, #6

2.0 LPBI – TNS #1:  Text Analysis with NLP, ML, AI

Proof of Concept in Cancer and Genomics is been developed for a Top Healthcare Insurer in UT.

• New cohort of INTERNS are joining LPBI on August 2020
• Text Analysis using Microsoft AZURE, NLP for Health  
• Proof of Concept will be design based on Text from the following THREE Sources and Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/07/21/wordcloud-visualization-of-lpbis-top-twelve-articles-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/

WordCloud Visualization of LPBI’s Top Sixteen Articles on CANCER in eight categories and by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curator: Stephen J. Williams, PhD and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD and Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2020/07/30/wordcloud-visualization-of-lpbis-top-sixteen-articles-on-cancer-in-eight-categories-and-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/

WordCloud Visualization of LPBI’s Top Sixteen Articles on GENOMICS by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curators: Stephen J. Williams, Aviva Lev-Ari, PhD, RN and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD https://pharmaceuticalintelligence.com/2020/07/30/wordcloud-visualization-of-lpbis-top-sixteen-articles-on-genomics-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/

2.0 LPBI – TNS #2: Blockchain Transaction Network Infrastructure – Partnership with World leader in the making. 

The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections 

• Work to start after Proof of Concept will be completed and All INSIGHTS will be used to narrowcast the articles by Research Categories. Using 12 Word Clouds for word-smithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered per communities specialties and the Article Titles available for download for $30 each.
• Front end design and narrow casting to Research Foundry and Communities on Partner’s Transaction System

2.0 LPBI – TNS #3: Audio-Video Podcasts Library  

• Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina

Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond

2.0 LPBI – TNS #4: Conversion of LPBI’s e-Book Series into 16 AUDIO BOOKS and

Text to Audio for each Article (N = 6,000)

• Strategy will be presented on August 18, 2020 Zoom Monthly Meeting

2.0 LPBI – TNS #5:  Joint Venture : 2.0 LPBI (30%) and Biotech Accelerator (70%)

President of the Biotech Accelerator had proposed on 7/21/2020: https://pharmaceuticalintelligence.com/calendar/

• Usage of Lab Space and Services of ABI LAB for the purpose of:
• Synthetic Biology Research on Galectins, See Table, below
• 2.0 LPBI Research Team: Ofer Markman, PhD and Irina Robu, PhD and Meg Baker, PhD 

More Details on 2.0 LPBI’s The New Strategies:

TNS #1, #2, #3, #4, #5, #6

TNS #1:  Text Analysis with NLP, ML, AI

THE PLAN; 4Q 2020 & 2021

TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health

• Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed byLPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery 
• Inputs for Proof of Concept are the following three:

(1) Top 12 articles by views (all domains) (2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1 (3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1

Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:

Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2

• Expand applications of Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
• Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
• Application on the ingress TEXT from:

Series C: e-Books on Cancer & Oncology

Volume 1:

Cancer Biology and Genomics for Disease Diagnosis

http://www.amazon.com/dp/B013RVYR2K 

Volume 2:

Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

http://www.amazon.com/dp/B071VQ6YYK 

and

Series B: Frontiers in Genomics Research

Volume 1: 

Genomics Orientations for Personalized Medicine

http://www.amazon.com/dp/B018DHBUO6

Volume 2:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

• The Wolfram Solution for Biological Sciences
• The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

LPBI Group’s FOUR Corpuses

(1) All 6,000 Journal Articles 

(2) 16 Books in Medicine 

(3) 60 e-Proceedings & 36 Tweet Collections of TOP Global Medical and Biotech Conferences, 2013 – 2020

(4) Content Segmentation by other criteria for Narrow casting the content of the journal ontology, Categories of Research (N = 715). About 70% are related to Drug DIscovery

The Voice of Ofer Markman, PhD

In 2020 and beyond, 2.0 LPBI brings to the Table:

• An Interdisciplinary Team of Experts 
• Deep Multiple Domains Knowledge
• Academic and Industry Recognition
• Remarkable e-Reputation on leading professional social media platforms, i.e., Twitter.com (The Leader for BioSciences Innovations announcements) and LinkedIn.com
• Global Expansive Business Connections
• Record of Unmatched Execution & Leadership

Dr. Ofer Markman

• Work to continue by All ACTIVE FIT Members in their expertise and ALL the INTERNS: current & new
•  Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications 
• Using Microsoft AZURE – NLP for Health for the Proof of Concept 
• For Cancer Volume 1 & 2 and Genomics Volume 1 & 2 – Comparison of Microsoft AZURE for Health with Text Analysis The Wolfram Language

On July 24, 2020, Dr. Williams on Methods to Improve the WordCloud images:

“So my suggestion would be actually to focus on the little words, which will give more insight into future targets, as the large words are well known. For example AKT, PI3K cancer is very well studied and dominates the literature. However, looking at some of the lesser ones, siRNA, targeting ,nuclear, complex, breast, targeted can one form into logical sentences which describe new avenues for research?” Also with the Word loud in media gallery readers can see a high definition image of it and then you can edit. Editing needs be done while on WordItOut.com platform before saved and exported.

On Sat, 8 Feb 2020 at 15:22 Aviva Lev-Ari <aviva.lev-ari@comcast.net> wrote:

UPDATED on 7/19/2020

The concept of HyperGraphDB and set of rules are needed to be created for the 1400 curations of Dr. Larry, more than half are about signaling pathways used in therapeutics using receptors.

THEN we will have the software for auto-independent semantic Text analysis of Dr. Larry’s UNIVERSE of articles – this was Dr. Williams great Idea.

(7/19/2020 – 5,875 (all articles) / 1400 (LHB’s Universe = 23.8%) of our IP in Journal articles.

Please read below, article and send me your comment on its relevance to our current search for a Partner with expertise in Machine Learning, Natural Language Processing, AI for text analysis.

https://www.wired.com/story/code-obsessed-novelist-builds-writing-bot-the-plot-thickens/

Example

Akt inhibition for cancer treatment, where do we stand today?

Article #11: WordCloud by DM

TNS #2: Blockchain Infrastructure – The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections

• Work to start upon completion of the Proof of Concept 

Using 12 Word Clouds for word-smithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered and the Article Titles available for download for $30 each.

• We wish to monetize the IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V
• Foundry Research is the community of Scientists built by a Partner – they had presented on 7/21 at 3PM EST 

The Voice of Stephen J. Williams, PhD, CSO, 1.0 LPBI

sjwilliamspa 

• Dr. Bernstein’s sub corpus of knowledge here or
• Dr. Fauci’s corpus of knowledge obtained from Pubmed) then one can
• Maps the Mind of any KOL in any given area

 

sjwilliamspa

• The ability of blockchain technology to offer secure, ledgered, and recorded transfer of data has only started to be utilized for literature, although mainly for transfer of secure electronic records involving healthcare records or business and legal documents.
• The use of blockchain for the secure, ledgered transfer/access to biomedical literature would be a novel undertaking. This type of technology would enhance legitimate transfer of data (articles) [a chief goal of 2.0 LPBI] while preventing the illegitimate transfer of those articles by data trollers.
• This could actually enhance the mission of 2.0 LPBI to rapidly and openly disseminate information. Blockchain will also allow better data management more under the control of an entity which own the corpus and allow analysis in real time by third party algorithms, given access through blockchain of said corpus (Agora of knowledge).
• Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case StudiesCurator and Editor-in-Chief: Journal and BioMed e-Series, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/ In addition,

• blockchain may assist in ways to incentivize the creators of knowledge in a sort of a self sustaining ecosystem. This has been tried by many open access journals where reviewers for the journal are given credits to defray publication costs
• therefore Value of Effort = monetized Value ($)
• this maintains the integrity of effort, the integrity of work and actually enhances it.
• Through blockchain technology this can run automated and unbiased.

The Voice of Daniel Menzin:

“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V”

1. Blockchain may be able to provide us with an organized way to keep track of each 30 dollar transaction. I would imagine their system would provide us with useful data as well which we can analyze like we’ve done with Twitter and WordPress. 

2. Since Blockchain is a shared ledger, it can distribute data across sites, institutions, or countries. This would allow us to organize all of our IP assets and transact with our buyer digitally, requiring less work to be done by the buyer in developing our existing infrastructure for their purposes I would imagine. 

3. It appears to me that Blockchain would improve the efficiency and ability to track our business transactions and documentation during our exit process. Blockchain claims to provide a shared digital medium for tracking the paperwork and agreements existing between two business parties. It is a shared, immutable ledger meaning that “it is a consensus of replicated, shared, and synchronized digital data geographically spread across multiple sites, countries, or institutions. Unlike with a distributed database, there is no central administrator.” It is immutable, meaning that the data cannot be changed once a consensus is reached (to my understanding). It seems like an automated digital system which serves to improve the organization and efficiency of business transactions by creating “a system” of sorts which organizes information related to these processes.

The Voice of Aviva Lev-Ari, PhD, RN:

“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI IP Asset Classes:

• I (Journal),
• II (e-Books),
• III (e-Proceedings+Tweet Collections),
• IV (Composition of Methods),
• V (Gallery of Biological Images)

These resources [1.0 LPBI: IP Asset Classes I, II, III, IV, V] could be accessed on a National level (Country x,y,z) or at the EU level or another geography (South East Asia) by

1. All Life Science Incubators
2. All Biotech Start ups
3. All Life Sciences Departments in any Higher EducationInstitute
4. All Medical Schools: Faculties using the content for curriculum development, Research Staff and Medical Students
5. All High school students writing Honor Final thesis in Life Sciences
6. All private individuals seeking knowledge in the Life Sciences & Medicine, Pharmaceutics and Health Care
7. Private & Public interests can be served: the Biotech/Healthcare sectors, Education Sectors, and
8. it can in parallel have a few business lines that are fully commercial for parties beyond Country x,y,z or the EU or another geography, i.e., Global and International NGOs such as Teva, IBM, GE Health, Siemens Healthineers, National’s HMOs can use the platform for Medical Doctors and Allied Health professionals continuing education using the contents of each of the three IP asset classes.

1. Blockchain may be able to provide us with a platform to narrowcast Word Cloud Images of

• 1.0 LPBI Journal Articles to the Research Foundry Community: Article Title (Live Link), Views, Categories of Research and Word Cloud Images
• A platform for selling Journal Articles, Books, e-Proceedings and Tweet Collections
• A Global Transaction System (GTS) generating Account Receivables and an Immutable ledger

2.  2.0 LPBI may be using Blockchain platform for the following functions:

1. Personalized Medicine,
2. Workflow Optimization,
3. High-Accuracy of 2.0 LPBI Article Buyer Directories,
4. Collaborative Research,
5. E-ID Programs,
6. National health Record Networks,
7. Health Information Exchanges,
8. Enterprise Data Networks,
9. Eligibility & Revenue Cycle,
10. Innovation Sandboxes,
11. Digital Therapeutics,
12. Reporting on Clinical Research

TNS #3: Audio-Video Podcasts Library

• Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina

Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond

Gail’s work:

Development Plan for e-VOICES Podcasting, 2019 – 2021*

https://pharmaceuticalintelligence.com/audio-podcasts/

*Dr. Williams and Aviva – will have their Podcasts in 2021.

Interview with Professor Marcus Feldman, Stanford University by Gail S. Thornton

https://pharmaceuticalintelligence.com/audio-podcasts/

Forthcoming

Gail’s Interview with Dr. Larry H. Bernstein, MA, FCAP 

• A Narrated Version – Tribute to his life long Contributions to Medicine
• LHB lost his voice in thyroid cancer in 2016, since then on Medical LEAVE @LPBI as CSO and Emeritus, Board Member

and

• On 3/12/2015 – Dr. Williams posted

Podcast Review: Quiet Innovation Podcast on Obtaining $ for Your Startup

Reporter: Stephen J. Williams, Ph.D.

https://pharmaceuticalintelligence.com/2015/03/12/podcast-review-quiet-innovation-podcast-on-obtaining-for-your-startup/

• On 1/25/2016 – Aviva posted

Launching LPBI’s, Fourth Line of Business (D): FIVE Podcast – Audio Series in BioMed

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

• On 3/17/2016 – Aviva posted

CRISPR: A Podcast from Nature.com on Gene Editing

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/03/17/crispr-a-podcast-from-nature-com-on-gene-editing/

TNS #4: Conversion of LPBI’s e-Book Series into AUDIO BOOKS

Strategy will be pursued in 2021

TNS #5:  Joint Venture : 2.0 LPBI and a Biotech Accelerator

President of the Biotech Accelerator proposed on 7/21/2020:

https://pharmaceuticalintelligence.com/calendar/

• Usage of Lab Space and Services of the Accelerator for the purpose of:
• Synthetic Biology Research on Galectins
• 2.0 LPBI Research Team: Ofer Markman, PhD and Irina Robu, PhD and Meg Baker, PhD 

•  Scientists love Synthetic Biology – designing drug molecules using Software – igem.org

  https://igem.org/Software A repository of open source software tools. Community driven data exchange standards. Specific software frameworks built explicitly for synthetic biology.

• INTERNS are joining after Labor Day – they need to gain some LAB Flavor in return for working as Volunteers @LPBI projects: SEE
•  2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates

Table of Human Galectins [edit]

https://en.wikipedia.org/wiki/Galectin#Table_of_Human_Galectins

UPDATED on 1/6/2020 CURATIONS of Scientific basic research findings and clinical interpretation by EXPERTS —>> Curations were what LPBI Group created since 4/2012 —>> Curations are the value we bring to a potential acquirer in the Life Sciences, Medicine, pharmaceutical domain. —>> We did it in three channels for knowledge dissemination OF OUR COLLABORATIVE formulations:   1. One Article Format of Curation by Experts was replicated by collaborations with other team members >5,700 TIMES 2. Expert Editors created electronic Table of Contents (eTOCs) for our 1st e-Book published 6/2013. We REPLICATED the process on eTOCs creation by Expert Editors SIXTEEN TIMES, 12/28/2019, last volume placed on the Medicine & Life Sciences in Kindle Store – our Genomics Volume 2 on AI in Medicine 3. 4/2013 was first BioIT Aviva covered in real time and created the first e-Proceedings, Dr. Williams created Twitter Analytics for it, WE IMPROVED AND REPLICATED this process >60 TIMES

• These three CORPUSES are seeking Transfer of Ownership and monetization in 2020.

TNS #6: e-Books Translations into Japanese, Spanish, Russian 

• Plan for 2021 TBD

@@@@@

UPDATED on 11/18/2019 The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation https://pharmaceuticalintelligence.com/2019/07/31/the-digital-age-gave-rise-to-new-definitions-new-benchmarks-were-born-on-the-world-wide-web-for-the-intangible-asset-of-firms-reputation-pay-a-premium-for-buying-e-reputation/ For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets https://pharmaceuticalintelligence.com/2019/08/06/twitter-analytics-engagement-rate-link-clicks-retweets-likes-replies-tweet-highlights-tweets-impressions-profile-visits-mentions-new-followers-for-aviva1950-founder-lpbi-group-ph/

UPDATED on 7/23/2019

Founder’s Vision

Dr. Aviva Lev-Ari, PhD, RN is an alumna of University of California, Berkeley, PhD’83. Dr. Lev-Ari was nominated for the 2019 Alumni of the Year Award followed by 2020 Campanile Excellence in Achievement Awards nomination forthcoming, 11/2019. August 2018-July 2021, Dr. Lev-Ari serves the Massachusetts Academies of Sciences (MAS) as Liaison to the Biotechnology and eScientific Publishing industries. She serves as Board member, Fellow, and Advisor to the Governing Board http://www.maacadsci.org. LPBI Group as a venture was launched in 4/2012 by Dr. Lev-Ari and she is leading it since its inception. These significant accomplishments were achieved in

• Pharmaceutical (Biomed e-Series, 16 volumes in the frontiers of Life Sciences and Medicine, average volume size: 2,400 pages, 96,000 page downloads),
• Media (e-Proceedings of Biotech Conferences, 70 events covered, 2013 to Present) and
• electronic Scientific Publishing (Open Access Online Scientific Journal, 1.7 Million readers, ~5,700 articles)

The growth in all the three domains, above, took place during that period and led to her nomination for the 2018 Yidan Prize. [Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/] Dr. Aviva Lev-Ari is the Director and Founder of a pharmaceutical media and digital scientific publishing group called Leaders in Pharmaceutical Business Intelligence (LPBI) Group, which owns the intellectual property in three interrelated healthcare content products:

1. IP Asset Class I.An on-line open access pharma scientific journal which has published about 5700 articles which have been read by over 1 1/2 million readers (1,640,034 as of 7/1/2019). http://pharmaceuticalintelligence.com 
2. IP Asset Class II.A series of 16 e-books in five medical specialities, including cardiovascular, genomics, cancer, immunology and precision medicine – these are available on Amazon https://lnkd.in/ekWGNqA
3. IP Asset Class III. An electronic corpus of the proceedings of 70 top Global Biomed scientific and Medical conferences. https://pharmaceuticalintelligence.com/press-coverage/

These three IP Asset Classes represent a vast IP portfolio owned by LPBI Group. We are currently exploring in North America, Europe and Southeast Asia, prospective acquisition opportunities for these IP resources [vast content, digital printed products, platform, methods, methodologies and systems]. A prospective acquirer would be an establishment, a corporation or an institute that will be able to carry these IP resources forward under new ownership and new management, as a new company. Following the knowledge transfer phase, the current team can continue pursuing their expertise under the new ownership and the new management. This is a concept of an M&A. Alternatively, a sale outright of the portfolio of IP could be considered under certain terms and conditions. It is Dr. Aviva Lev-Ari’s belief that this newly to be established organizational entity would provide employment to dozens of Postdocs in the Life Sciences, who face a small number of Academic openings in the LIfe Sciences in the developed countries. It will attract Medical Doctors interested in writing clinical interpretations to basic life sciences primary research outcomes using the methodology of curation for scientific findings developed by Dr. Lev-Ari and her Team as demonstrated in the 5,700 articles in the Journal mentioned above which to date had attracted ~8000 comments by Scientist eReaders around the Globe using in search the +10,000 tags and the 670 categories of research which form the Ontology of the Journal. Following such a transaction, these three vast IP assets will be hosted on a Cloud Web Services platform architecture managed by the new ownership and offering to the Public the advantages of global accessibility [under terms and conditions]. These resources could be accessed on a National level (Country x,y,z) or at the EU level or another geography by

1. All Life Science Incubators
2. All Biotech Start ups
3. All Life Sciences Departments in any Higher EducationInstitute
4. All Medical Schools: Faculties using the content for curriculum development, Research Staff and Medical Students
5. All High school students writing Honor Final thesis in Life Sciences
6. All private individuals seeking knowledge in the Life Sciences & Medicine, Pharmaceutics and Health Care
7. Private & Public interests can be served: the Biotech/Healthcare sectors, Education Sectors, and
8. it can in parallel have a few business lines that are fully commercial for parties beyond Country x,y,z or the EU or another geography, i.e., Global and International NGOs such as Teva, IBM, GE Health, Siemens Healthineers, National’s HMOs can use the platform for Medical Doctors and Allied Health professionals continuing education using the contents of each of the three IP asset classes.

Human Capital and the Content Creation Process

• The two Board Members, Dr. Stephen J. Williams and Dr. Marcus W. Feldman are fully involved in venture’s decision making activities.
• The LPBI Group’s team members are all Experts, Authors, experienced Writers professing the Curation methodology applied for content creation in Translational Medicine from Life Sciences to bedside Medicine, Genomics, Bioinformatics, AI in Radiology and Pathology and Precision Medicine, Cancer, Cardiovascular diseases and Cardiac Imaging, Immunology, Infectious diseases, BioMedicine, Biotechnology, Pharmaco-therapy, Medical Technology and Health Care.

In House Business and Management Tool Development

• The LPBI Group’s Business Team had developed an extensive business plan for the potential acquirers of these three IP asset classes. Twelve industries were identified. The Business Plan and the Opportunities Map are ready for perusal.

https://pharmaceuticalintelligence.com/2019-vista/

• Full documentation of Intangible and of Tangible assets is updated quarterly.

2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 

• The team developed a calculator for valuation of LPBI Group’s IP by contributing factors to value creation [in beta phase: IP-VAL-CALC]
• The Opportunities Map, the Business plan and a detailed document describing the technology and the pipeline of new products and Content as a Service (CAAS), all three can be used for design of new PowerPoint Presentations in different languages customized to each acquirer’s identified industry, within each of the 12 industries. A Presentation per industry, presented to several potential acquirers within each industry.

Dr. Lev-Ari is bringing to the table a business candidate for an acquisition of the Intellectual property vast portfolio – three asset classes for common access by the entire BIOTECH Industry in Country x,y,z or the EU or another geography. The leading Global Conference Organizers for Global audiences in Biotech would benefit from IP Class III, and make it a product they currently do not have. Dr. Lev-Ari is interested in finding half a dozen appropriate potential acquirers, preferably in several geographies, who would champion the technology, the infrastructure, and the contents in Health care to continue this amazing series of accomplishments in three Industries:

1. Pharmaceutical (BioMed eBooks),
2. Media (e-Proceedings) and
3. electronic Scientific Publishing (Journal).

UPDATED on 2/10/2019 Leaders in Pharmaceutical Business Intelligence (LPBI) Group is an electronic scientific publishing venture that has developed platform architecture methodologies and business models of intellectual property development via scientific content creation by curation. These aspects of our intellectual property assist the e-Scientific Publishing Industry and scientific information users to mitigate the information explosion of scientific articles in the Life Sciences and Medicine and their inevitable immediate obsolescence. The work produced by LPBI Group is a team effort within the key domains of BioMed, BioTech, Pharmaco-therapy, MedTech, Health Care and the Life Sciences-Medicine connection. Our system technologies, which include platforms, methodologies and models, also include development of significant content materials. Additionally, this work can be replicated in many fields, i.e., Legal, Economics, Finance, International Relations, as examples of disciplines. It should be noted that all of LPBI’s material could, in principle, be translated into other languages. All members of our team have at least 10 years of experience in the life sciences area and have been trained to master the methodology of scientific curation used in our articles, in turn, if selected by experienced editors, these articles are targeted for inclusion in our books. The members of the team include senior MDs, MD/PhDs, FACC, FCAP, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes. Highly qualified content consultants are involved in each of the five e-series (senior MDs, MD/PhDs, and Professors) are engaged in the production of our curations. The topics for article curations and for the contents of the books we have created are carefully edited; I am the editor-in-chief and lead this multidisciplinary content compilation using my diverse areas of technical training and experience. Our intellectual property “IP” consists of three classes of assets as described in detail within live links in the below, listed article.

• First, the Journal, an ongoing journal of curated, current biomedical research;
• Second, the books, a collection of 16 volumes of e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomics, Cancer, Immunology and Precision Medicine; and
• Third, real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in One-click operation.

These three IP asset classes are described in details with live links in eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/ LPBI’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. We have shown that synergy among experts, authors and writers yields outstanding collaborations in producing our curations. There are many post-doctoral individuals in biotech industries and academia who can serve as experts, authors and writers in continuing LPBI’s operations, following appropriate onboarding. The link, above is a summary of six demonstrations that justify these claims. The list of six points is followed by an extensive description of these valuable attributes of LPBI IP. The table for POINT #4 presents a concise summary of the functions and forms of LPBI IP three asset classes.   UPDATED on 12/4/2018

UPDATED on 4/2/2018

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

Material below that point is OUTDATED 

This section is under construction

MultiMedia Presence

• Twitter.com: http://twitter.com/pharma_BI

@pharma_BI

• FaceBook Page

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

• Launchers of a Professional Group on LinkedIn

http://www.linkedin.com/groups?gid=4346921&trk=hb_side_g

• Company Page on LinkedIn

https://www.linkedin.com/company/9325543?trk=vsrp_companies_res_name&trkInfo=VSRPsearchId%3A875971435604472931%2CVSRPtargetId%3A9325543%2CVSRPcmpt%3Aprimary

e-Book Titles by LPBI

For more information on Real-Time Conference Coverage and a full listing of Conferences Covered by LPBI please go to:

https://pharmaceuticalintelligence.com/press-coverage/

Leaders in Pharmaceutical Business Intelligence is a Holding Company of Six Ventures:

Venture Overview Updated in New Company Page on LinkedIn: Leaders in Pharmaceutical Business Intelligence – 3/7/2015 https://pharmaceuticalintelligence.com/2015/03/07/venture-overview-updated-on-new-company-page-on-linkedin-leaders-in-pharmaceutical-business-intelligence/

• VENTURE #1:

e-Publishing: Medicine, HealthCare, Life Sciences, BioMed, Pharmaceutical– Open Access Online Scientific Journal http://pharmaceuticalintelligence.com

• VENTURE #2:

BioMedical e-Books e-Series: Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine https://pharmaceuticalintelligence.com/biomed-e-books/

2013 e-Book on Amazon.com

Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013

http://www.amazon.com/dp/B00DINFFYC

2015 e-Book on Amazon.com

1. Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015

http://www.amazon.com/dp/B012BB0ZF0 2. Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015 http://www.amazon.com/dp/B013RVYR2K

3. Genomics Volume One

4. Physiology, Genomics and Pharmaceutical

5. Cardiovascular, Volume Two: Co-Curation, Methodology

6. Cardiovascular Diseases, Volume Three: Etiology, Genetics and Genomics

7. Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine

8. Cancer Volume Two: Immunotherapy, Nanotechnology in drug delivery

2016 we need to FIND Editors for Two e-Books

– Genomics Volume Two on NGS – Dr. Williams and another Editor

– Patient Voice on Invasive Procedures – New Editor

2016, We will continue with

– Aviva will work with Larry on CVD 5: Pharmacology-Therapy, 

– With Adam and Dr. Pearlman, on CVD 6: Cardiac Surgery and Interventional

– With Adam and Dr. Pearlman, on CVD 7: CV Imaging

– Dr. Pearlman alone: 

Three CVD Hardcopy Volumes, 1-Etiology, 2-Diagnostics, 3-Therapies

• VENTURE #3:

International Scientific Delegations https://pharmaceuticalintelligence.com/scientific-delegation

• VENTURE #4:

Funding, Deals & Partnerships https://pharmaceuticalintelligence.com/joint-ventures/

Business Development Plan for LPBI

– investors in Shanghai, China for funding Biologics and Medical Devices (Wilferd van Opstal)

– investors in Switzerland to find an e-Publisher to buy the Journal and the e-Books (Gerard Loiseau)

– a 3D Printing Swiss company – RegenHU — to establish Partnerships with MIT, GE, J&J [Adam on P&G]

– Adam drafts Patents with Bill Zurn on implantable Cardiovascular device – I am discussing Zurn’s IP with investors in Shanghai and NYC

– I work with investors in NYC (Nicholas Hall, Private Wealth Management, Maxim Group LLC) on Deals, Funding and Partnerships

• VENTURE #5:

IP Invented HERE!

• VENTURE # 6:

Real Time PRESS Coverage International Biotech Conferences https://pharmaceuticalintelligence.com/press-coverage/

Our Growth Needs: Leaders in Pharmaceutical Business Intelligence

 Our Business Portfolio

VENTURE #1:

e-Publishing: Medicine, HealthCare, Life Sciences, BioMed, Pharmaceutical

• Open Access Online Scientific Journal

11/19/2014 – PRESS RELEASE — Over 500,000 Unique Site Visits reached by PharmaceuticalIntelligence.com Reported today by Leaders in Pharmaceutical Business Intelligence (LPBI) https://pharmaceuticalintelligence.com/2014/11/19/over-500000-unique-site-visits-reached-by-pharmaceuticalintelligence-con-reported-today-by-leaders-in-pharmaceutical-business-intelligence-lbpi/ http://pharmaceuticalintelligence.com

• Scoop.it!.com

1. http://www.scoop.it/t/cardiotoxicity
2. http://www.scoop.it/t/cardiovascular-and-vascular-imaging
3. http://www.scoop.it/t/cardiovascular-disease-pharmaco-therapy

VENTURE #2:

1. BioMedical e-Books e-Series: Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/

• Series A: e-Books on Cardiovascular Diseases
• Series B: Frontiers in Genomics Research
• Series C: e-Books on Cancer & Oncology
• Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases
• Series E: Titles in the Strategic Plan for 2014-2015

2. on Amazon’s Kindle e-Books List since 6/2013

• Perspectives on Nitric Oxide in Disease Mechanisms

3. Plans for Volume 1,2,3 – Hardcover

• Cardiovascular Diseases: Causes, Risks and Management – Volume 1,2,3 – Hardcover

4. Schedule Plan for e-Publishing on Amazon.com

• Publishing on Amazon Kindle – SIX Volumes in 2015:

1.  Metabolomics, Volume One 2.  Genomics, Volume One 3.  Cancer Volume One 4.  Cardiovascular – Volume 2 5.  Cardiovascular – Volume 3 6.  Cardiovascular – Volume 4

• Publishing on Amazon Kindle – Four Volumes in 2016:

1.  Physiology, PharmacoTherapy and Genomics: The Patient-centered Medicine Perspective 2.  Cancer, Volume Two 3.  Cardiovascular – Volume 5 4.  Cardiovascular – Volume 6

VENTURE #3:

International Scientific Delegations https://pharmaceuticalintelligence.com/scientific-delegation/

• Shanghai, May 2015
• Barcelona, Spain, November 2015
• Amsterdam, May 2016
• Geneva, November 2016

VENTURE #4: 

Funding, Deals & Partnerships

https://pharmaceuticalintelligence.com/joint-ventures/

• Corporate Clients for our Services
• Funding Cardiovascular Medical Devices Development
• Funding Biologics Development
• Funding Diagnostics
• Funding Partnerships in IP Development
• M&A and Exit
• Targeting Penetration in New Markets for High Technology Products
• Management of Engineering Design of Prototypes Outsourcing

VENTURE #5:

IP Invented HERE!

1.  Development of a NEW Nitric Oxide monitor to Alpha Szenszor Inc. sensor portfolio. A concept for a low cost POC e-nose, capable of real time ppb detection of Cancer The Cancer Team at Leaders in Pharmaceutical Business Intelligence under the leadership of Dr. Williams 2.  Development of a NEW Nitric Oxide monitor to Alpha Szenszor Inc. sensor portfolio. A concept for Inhaled Nitric Oxide for the Adult HomeCare Market – IP by Dr. Pearlman and Dr. A. Lev-Ari a.  iknow iNO is i-kNOw – Inhaled Nitric Oxide for the HomeCare Market https://pharmaceuticalintelligence.com/2013/10/16/iknow-ino-is-i-know-inhaled-nitric-oxide-for-the-homecare-market/ b. electronic Book on Nitric Oxide by Nitric Oxide Team @ Leaders in Pharmaceutical Business Intelligence (LPBI) Perspectives on Nitric Oxide in Disease Mechanisms http://www.amazon.com/dp/B00DINFFYC c. The rationale and use of inhaled NO in Pulmonary Artery Hypertension and Right Sided Heart Failure Larry H. Bernstein 8/20/2012 d. Inhaled Nitric Oxide in Adults: Clinical Trials and Meta Analysis Studies – Recent Findings Aviva Lev-Ari, PhD, RN, 6/2/2013 e. Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care Aviva Lev-Ari, PhD, RN, 6/3/2013 3.  Cancer Genomics for NEW product development in diagnosis and treatment of Cancer Patients using sensory technology with applications for Radiation Therapy – The Cancer Team at Leaders in Pharmaceutical Business Intelligence under leadership of Dr. Larry H Bernstein, MD, FCAP 4.  Developing Mitral Valve Disease: MRI Methods and Devices for Percutaneous Mitral Valve Replacement and Mitral Valve Repair Augmentation of Patented Technology using RF – Dr. Pearlman’s IP Non-Hardware Mitral Annuloplasty – Dr. Justin D. Pearlman https://pharmaceuticalintelligence.com/joint-ventures/valvecure-llc/non-hardware-mitral-annuloplasty-dr-justin-d-pearlman/ 5.  Novel Technology using MRI for Vascular Lesions, Tumors, Hyperactive Glands and non-Surgical Cosmetic Reconstruction – Dr. Pearlman’s IP http://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/httppharmaceuticalintelligence-combiomed-e-bookscardiovascular-diseases-causes-risks-and-management/cvd-business-affairs/mitral-valve-disease-mri-methods-and-devices/

VENTURE # 6:

PRESS Coverage of Conferences

https://pharmaceuticalintelligence.com/press-coverage/

This page has the following sub pages.

• 2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets
• PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views